ArticleEcancermedicalscience2026
Age and sex-based differences in therapy preferences among patients with cancer: evidence from a novel therapy preference scale.
Article in Ecancermedicalscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Patients' preferences are crucial to formulating personalised treatment plans. We developed a self-reported questionnaire, therapy preference scale (TPS), to examine treatment preferences of patients with cancer. Methods: TPS has 30 questions: 19 on patients' preferences on safety, quality of life and treatment effectiveness, 8 questions on the importance of various treatment characteristics and 3 on patients' preferred intent of therapy, expenses and life expectancy gain. We recruited 300 adults >18 years with a cancer diagnosis and categorised them into 4 age-by-sex groups (younger men <60 years, older men ≥60 years, younger women< 60 years, older women ≥60 years). Kruskal-Wallis non-parametric ANOVA method was used to compare responses among four groups. Results: Older women, compared to other groups, were more likely to value maintenance of cognitive function and ability to perform daily activities. Older women were more likely to risk having a shorter life expectancy rather than facing the risk of long-term cognitive impairments. Younger men and women were more likely to accept more effective treatment, even if it caused significant pain. A higher percentage of younger men, compared to other groups, valued maintaining sex life. Older men and women were more likely to prefer oral pills over intravenous therapy. Conclusion: Patient preferences may vary based on age and sex, with older women prioritising cognitive and physical function independence more frequently, whereas younger men and women are willing to pursue more effective treatment options even with a greater risk of significant pain. TPS can elicit detailed preferences of an individual patient to facilitate shared decision-making with their oncologists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.